KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) EBIT (2016 - 2025)

Pacific Biosciences Of California has reported EBIT over the past 16 years, most recently at -$41.2 million for Q4 2025.

  • Quarterly results put EBIT at -$41.2 million for Q4 2025, up 73.08% from a year ago — trailing twelve months through Dec 2025 was -$553.9 million (down 16.77% YoY), and the annual figure for FY2025 was -$553.9 million, down 16.77%.
  • EBIT for Q4 2025 was -$41.2 million at Pacific Biosciences Of California, down from -$38.9 million in the prior quarter.
  • Over the last five years, EBIT for PACB hit a ceiling of -$33.7 million in Q1 2021 and a floor of -$428.9 million in Q1 2025.
  • Median EBIT over the past 5 years was -$74.6 million (2022), compared with a mean of -$95.0 million.
  • Peak annual rise in EBIT hit 74.49% in 2025, while the deepest fall reached 427.19% in 2025.
  • Pacific Biosciences Of California's EBIT stood at -$64.7 million in 2021, then plummeted by 34.65% to -$87.1 million in 2022, then decreased by 0.53% to -$87.5 million in 2023, then crashed by 74.79% to -$153.0 million in 2024, then soared by 73.08% to -$41.2 million in 2025.
  • The last three reported values for EBIT were -$41.2 million (Q4 2025), -$38.9 million (Q3 2025), and -$44.9 million (Q2 2025) per Business Quant data.